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the association between folic acid supplementation and birth defects other than neural tube defects 
remains unclear. We utilized data from a large population-based survey to examine the association 
between folic acid supplementation and birth defects in Northwestern China. A total of 29,204 
women with infants born between 2010 and 2013 were surveyed in Shaanxi province, Northwestern 
China, using a stratified multistage sampling method. Propensity scores were used to match 9,293 
women with optimal folic acid supplementation with 9,293 women with nonoptimal folic acid 
supplementation, and the effects of optimal folic acid supplementation on birth defects were assessed 
by a conditional logistic regression model. After propensity score matching, the overall birth defect 
rate, cardiovascular system defect rate and nervous system defect rate for the women with optimal folic 
acid supplementation were lower than those for the women with nonoptimal folic acid supplementation 
(overall birth defects: oR = 0.71, 95% CI = 0.57–0.89, P = 0.003; cardiovascular system defects: 
oR = 0.65, 95% CI = 0.44–0.96, P = 0.032; nervous system defects: OR = 0.13, 95% CI = 0.02–0.99, 
p = 0.049). Optimal folic acid supplementation was associated with a decreased prevalence of birth 
defects, especially in the cardiovascular system and nervous system. Our findings have important 
implications for birth defect intervention with folic acid supplementation for countries with a high 
prevalence of birth defects, such as China.
“Birth defect” is a general term for functional or structural abnormalities in a developing fetus. Some birth defects 
are caused by known genetic factors, such as chromosome aberrations or genetic mutations, environmental fac-
tors, or interactions between genetic factors and environmental factors. Birth defects are the leading cause of early 
miscarriage, stillbirth, perinatal death, and infant and child death1. Approximately 5.6% of pregnancies in China, 
including both live births and pregnancy losses, are affected by birth defects2. There are approximately 0.25 mil-
lion births with major defects every year in China, which leads to a substantial disease burden2.
Both randomized controlled studies and observational studies have confirmed that periconceptional folic 
acid supplementation can reduce the prevalence of neural tube defects3–6. The WHO recommends that all women 
should take a folic acid supplement from the period before conception until 12 weeks of gestation7. In line with 
the WHO recommendation, China has issued a policy of folic acid supplementation (folic acid supplement 
≥400 µg/d) during the 3 months before pregnancy and the first trimester of pregnancy. All Chinese women of 
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childbearing age have access to free folic acid. The policy has played a very important role in significantly pre-
venting neural tube defects (NTDs) in China2. However, the relationships between periconceptional folic acid 
supplementation and other birth defects, such as cardiovascular system defects, oral clefts, and urinary system 
defects, remain inconclusive. Interpretations of findings from observational studies are often limited by potential 
residual biases from measured confounders and possible biases resulting from unmeasured confounders. The 
propensity score (PS) technique has emerged as an effective tool to address selection and residual biases, and PS 
methods allow the transparent design and analysis of observational studies8–10. The objective of this study was to 
investigate the association between periconceptional folic acid supplementation and birth defects using PS meth-
ods in Shaanxi province, Northwest China.
Results
participant characteristics. Among the birth defects surveyed, we identified 192.44 cases (per 10,000 
infants) of overall birth defects before PS matching, including 6.85 cases (per 10,000 infants) of nervous system 
defects; 23.97 cases (per 10,000 infants) of eye, ear, face and neck defects;, 63.35 cases (per 10,000 infants) of car-
diovascular system defects; 3.77 cases (per 10,000 infants) of respiratory system defects; 11.64 cases (per 10,000 
infants) of oral clefts; 8.56 cases (per 10,000 infants) of digestive system defects; 5.82 cases (per 10,000 infants) of 
genital organ defects; 2.05 cases (per 10,000 infants) of urinary system defects; 34.58 cases (per 10,000 infants) of 
musculoskeletal system defects; 0.68 cases (per 10,000 infants) of chromosomal abnormalities; and 31.16 cases 
(per 10,000 infants) of other defects (Table 1).
Among the matched participants, 20.79% were ≥30 years, 46.38% had ≥9 years of education, 0.43% were 
non-Han, and 35.95% were urban residents. Table 2 compares the participants’ baseline characteristics according 
to folic acid supplementation before and after PS matching. There were significant prematch imbalances in several 
important covariates, including multiple births and tobacco exposure, that were balanced after matching. Our 
PS matching reduced the standardized differences for all covariates below 10% in absolute value, demonstrating 
substantial improvement in covariate balance across the folic acid supplementation groups (Fig. 1).
optimal folic acid supplementation and birth defects. After PS matching, there were 195.85 cases per 
10,000 infants in the nonoptimal folic acid supplementation group and 138.89 cases per 10,000 infants in the opti-
mal folic acid supplementation group (OR = 0.71; 95% CI = 0.57–0.89; P = 0.049). Compared with 8.61 nervous 
system defects per 10,000 infants in the nonoptimal folic acid supplementation group, there were 1.08 nervous 
system defects per 10,000 infants in the optimal folic acid supplementation group (OR = 0.13; 95% CI = 0.02–
0.99; P = 0.049). Compared with 67.79 cardiovascular system defects per 10,000 infants in the nonoptimal folic 
acid supplementation group, there were 44.12 cardiovascular system defects per 10,000 infants in the optimal folic 
acid supplementation group (OR = 0.65; 95% CI = 0.44–0.96; P = 0.032) (Table 3). Among cardiovascular system 
defects, the pregnancy outcomes of the optimal folic acid supplementation group were less likely to involve ven-
tricular septal defects, atrial septal defects and patent ductus arteriosus than those of the nonoptimal folic acid 
supplementation group (ventricular septal defect: OR = 0.58, 95% CI = 0.30–1.13, P = 0.109; atrial septal defect: 
OR = 0.83; 95% CI = 0.36–1.93, P = 0.672; patent ductus arteriosus: OR = 0.43, 95% CI = 0.17–1.12, P = 0.083). 









Nervous system 18 (9.67) 2 (1.89) 20 (6.85)
Eye, ear, face and neck 51 (27.40) 19 (17.94) 70 (23.97)
Cardiovascular system defect 131 (70.39) 54 (50.98) 185 (63.35)
  Ventricular septal defect 42 (22.57) 15 (14.16) 57 (19.52)
  Atrial septal defect 29 (15.58) 14 (13.22) 43 (14.72)
  Patent ductus arteriosus 26 (13.97) 7 (6.61) 33 (11.30)
  Pulmonary artery constriction 10 (5.37) 5 (4.72) 15 (5.14)
  Atrioventricular septal defect 6 (3.22) 4 (3.78) 10 (3.42)
  Tetralogy of Fallot 5 (2.69) 3 (2.83) 8 (2.74)
  Others 13 (6.99) 6 (5.66) 19 (6.51)
Respiratory system 8 (4.30) 3 (2.83) 11 (3.77)
Oral clefts 28 (15.04) 6 (5.66) 34 (11.64)
Digestive system 15 (8.06) 10 (9.44) 25 (8.56)
Genital organs 10 (5.37) 7 (6.61) 17 (5.82)
Urinary system 4 (2.15) 2 (1.89) 6 (2.05)
Musculoskeletal system 72 (38.69) 29 (27.38) 101 (34.58)
Other defects 64 (34.39) 27 (25.49) 91 (31.16)
Chromosomal abnormalities 1 (0.54) 1 (0.94) 2 (0.68)
Total birth defects 402 (216.00) 160 (151.04) 562 (192.44)
Table 1. Prevalence of birth defects in infants (per 10,000 infants).
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pulmonary artery constriction, atrioventricular septal defects and tetralogy of fallot and folic acid supplementa-
tion were not statistically significant.
After PS matching, the pregnancy outcomes of the optimal folic acid supplementation group were less likely 
to include eye, ear, face and neck defects; respiratory system defects; oral clefts and digestive system defects 
than those of the nonoptimal folic acid supplementation group (eye, ear, face and neck defects: OR = 0.50, 95% 
CI = 0.25–1.01, P = 0.055; respiratory system: OR = 0.75, 95% CI = 0.17–3.35, P = 0.706; oral clefts: OR = 0.46, 
95% CI = 0.18–1.21, P = 0.117; digestive system: OR = 0.67, 95% CI = 0.32–2.41, P = 0.796). However, the rela-
tionships between folic acid supplementation and respiratory system defects, oral clefts, digestive system defects, 
abnormalities of the genital organs, urinary system defects, musculoskeletal system defects, chromosomal abnor-
malities and other defects were not statistically significant.
sensitivity analyses. In the full (prematched) group of participants (n = 29204), there were 216.00 cases of 
birth defects per 10,000 in the nonoptimal folic acid supplementation group, compared with 151.04 cases of birth 





Optimal folic acid 
supplementation 





Optimal folic acid 
supplementation 
n = 9,293 P value
Child sex (boys) 10319 (55.45) 5684 (63.66) 0.003 5067 (54.52) 5038 (54.21) 0.669
Multiple births 201 (1.08) 151 (1.43) 0.009 71 (0.76) 84 (0.90) 0.294
Pregnancy age ≥30 
years 4510 (24.23) 2385 (22.51) 0.001 1904 (20.49) 1960 (21.09) 0.311
Maternal education 
(≥9 years) 5732 (30.80) 5429 (51.25) <0.001 4311 (46.39) 4310 (46.39) 0.988
Non-Han 100 (0.53) 87 (0.82) 0.003 34 (0.37) 45 (0.48) 0.215
Residence (urban) 5245 (28.18) 4322 (40.80) <0.001 3334 (35.88) 3347 (36.01) 0.842
Wealth index (rich) 8797 (47.27) 5801 (54.76) <0.001 4918 (52.92) 4940 (53.16) 0.746
First pregnancy 8755 (47.04) 6171 (58.26) <0.001 5314 (57.18) 5296 (56.99) 0.790
Preterm birth history 549 (2.95) 267 (2.52) 0.032 167 (1.80) 177(1.90) 0.586
Abortion history 2500 (13.43) 1557 (14.70) 0.003 1254 (13.49) 1255 (13.50) 0.983
Pregnancy infection 2370 (12.73) 1451 (13.70) 0.019 1111 (11.96) 1136 (12.22) 0.574
Birth at a township 
hospital 2519 (13.54) 1129 (10.66) <0.001 986 (10.61) 983 (10.58) 0.943
Pesticide exposure 269 (1.45) 70 (0.66) <0.001 37 (0.40) 51 (0.55) 0.135
Tobacco exposure 11366 (61.07) 5993 (56.58) <0.001 5433 (58.46) 5398 (58.09) 0.603
Adverse events 
exposure 1374 (7.38) 587 (5.54) <0.001 424 (4.56) 460 (4.95) 0.215
Occupational risk 
exposure 1607 (8.63) 807 (7.62) 0.002 610 (6.56) 637 (6.85) 0.429
Environment risk 
exposure 5145 (27.64) 2621 (24.74) <0.001 2233 (24.03) 2243 (24.14) 0.864
Table 2. Baseline participant characteristics by folic acid supplement before and after propensity score (PS) 
matching (%).
Figure 1. Absolute standardized differences before and after propensity scores matching comparing covariate 
values for participants with optimal folic acid supplementation and nonoptimal folic acid supplementation.
4Scientific RepoRts |          (2019) 9:5271  | https://doi.org/10.1038/s41598-019-41584-5
www.nature.com/scientificreportswww.nature.com/scientificreports/
defects per 10,000 in the optimal folic acid supplementation group (OR = 0.70; 95% CI = 0.58–0.84; P < 0.001). 
Compared with 9.67 cases of nervous system defects per 10,000 in the nonoptimal folic acid supplementation 
group, there were 1.89 cases of nervous system defects per 10,000 in the optimal folic acid supplementation 
group (OR = 0.20; 95% CI = 0.5–0.84; P = 0.028). Compared with 70.39 cases of cardiovascular system defects 
per 10,000 in the nonoptimal folic acid supplementation group, there were 50.98 cases of cardiovascular system 
defects per 10,000 in the optimal folic acid supplementation group (OR = 0.72; 95% CI = 0.53–0.99; P = 0.045). 
When we adjusted for PS, the association remained significant (birth defects: OR = 0.70, 95% CI = 0.58–0.89, 
P = 0.003; nervous system defects: OR = 0.20, 95% CI = 0.05–0.84, P = 0.030; cardiovascular system defects: 
OR = 0.72, 95% CI = 0.45–0.99, P = 0.032). There were no significant differences in other defects between the 
folic acid supplementation groups.
Among the participants in PS tertiles two and three (n = 19936), we observed similar effects on optimal folic 
acid supplementation on birth defects, nervous system defects and cardiovascular system defects: PS-adjusted 
(birth defects: OR = 0.79, 95% CI = 0.65.−0.95, P = 0.013; nervous system defects: OR = 0.21, 95% CI = 0.05–
0.87, P = 0.031; cardiovascular system defects: OR = 0.72, 95% CI = 0.52–0.99, P = 0.047).
Discussion
Shaanxi province is a high-prevalence area of birth defects in Northwest China. The overall prevalence of birth 
defects and cardiovascular system defects in Shaanxi province is higher than the national average and the aver-
ages for other provinces in Northwest China2. Thus, the prevention of birth defects and improvement of popula-
tion health in Shaanxi province, Northwest China, are urgently necessary. This study investigated the association 
between folic acid supplementation and the birth defect spectrum, and our findings demonstrated that optimal 
folic acid supplementation was associated with a decreased risk of overall birth defects in Northwest China, espe-
cially nervous system and cardiovascular system defects. Optimal folic acid supplementation was not found to 
be associated with a significant decrease in other defects. These findings are very important because of the high 
prevalence of birth defects and the inconsistent rate of periconceptional folic acid supplementation in Northwest 
China.
Nervous system defects, especially NTDs, are common congenital anomalies in China. Nervous system defects 
always occur very early in pregnancy. The prevalence of NTDs was 13.8 per 1,000 births in 1999 in northern 
China, compared with less than 1 per 1,000 births in the USA11,12. A China-U.S. collaborative project for neural 
tube defect prevention conducted in northern and southern China revealed an 85% reduction in NTD risk in the 
northern region and a 40% reduction in NTD risk in the southern region6. Consequently, folic acid supplementa-
tion had a much greater effect on reducing the occurrence of NTDs in China. In our study, a lower prevalence of 
6.85 per 10,000 infants was also observed. A large number of clinical trials and observational studies have shown 
that folic acid supplementation during pregnancy reduced the prevalence and recurrence rate of NTDs13–16, and 
an ecological study found that the prevalence of anencephaly and spina bifida decreased to 11% from 20% and to 
21% from 34%, respectively, after folic acid fortification17. Our study was based on a birth defects survey in folate 
deficient areas in Northwestern China, and focused on the association between folic acid supplementation and 
birth defects. Although folic acid supplementation prevents NTDs, the dosage of folic acid supplementation and 
the duration of folic acid supplementation in practice are not consistent among different countries and regions 
of the world7, which are still of great impact on the prevention of NTDs. Our study provides additional evidence 
that optimal folic acid supplementation during the periconceptional period is associated with a reduction in the 
prevalence of nervous system defects (OR = 0.13; 95% CI = 0.02–0.99; P = 0.049). Therefore, our study further 
OR (95% CI) P value
Nervous system 0.13 (0.02–0.99) 0.049
Eye, ear, face and neck 0.50 (0.25–1.01) 0.055
Cardiovascular system defect 0.65 (0.44–0.96) 0.032
  Ventricular septal defect 0.58 (0.30–1.13) 0.109
  Atrial septal defect 0.83 (0.36–1.93) 0.672
  Patent ductus arteriosus 0.43 (0.17–1.12) 0.083
  Pulmonary artery constriction 1.00 (0.25–4.00) 0.999
  Atrioventricular septal defect 1.00 (0.20–4.96) 0.999
  Tetralogy of Fallot 1.50 (0.24–9.00) 0.658
Respiratory system 0.75 (0.17–3.35) 0.706
Oral clefts 0.46 (0.18–1.21) 0.117
Digestive system 0.67 (0.32–2.41) 0.796
Genital organs 1.50 (0.42–5.32) 0.530
Urinary system 1.00 (0.06–15.99) 0.999
Musculoskeletal system 1.00 (0.57–1.76) 0.999
Other defects 0.93 (0.55–1.58) 0.785
Chromosomal abnormalities 1.00 (0.06–15.99) 0.999
Total birth defects 0.71 (0.57–0.89) 0.003
Table 3. OR and 95% CI for birth defects by optimal folic acid supplement in conditional logistic regression.
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added to support for the reduction of nervous system defects by means of folic acid supplementation during the 
periconceptional period.
Cardiovascular system defects rank first among birth defects in China. The prevalence of cardiovascular sys-
tem defects was 10~20 per 1,000 during the fetal period and 8~10 per 1,000 in live births18. From 2000 to 2011, 
the overall birth defect prevalence rates showed a downward trend. The National Stocktaking Report on Birth 
Defect Prevention (2012) (China) reported that the prevalence rate of cardiovascular system defects increased 
between 2000 and 20112. Some studies have confirmed that the use of vitamin supplements containing folic acid 
in early pregnancy was associated a reduced risk of cardiovascular system defects in offspring. Ionescuittu com-
pared the prevalence of severe congenital heart disease before and after folic acid fortification in Quebec province, 
Canada19. The results showed that there was a significant 6% decrease per year (OR = 0.94; 95% CI = 0.90–0.97) 
in the seven years after folic acid fortification began. Liu carried out a population-based cohort study of all live 
births and stillbirths in Canada and found that folic acid fortification was associated with lower rates of nonchro-
mosomal heart defects (OR = 0.89; 95% CI = 0.82–0.98)20. A 1984–1991 Hungarian randomized controlled trial 
(RCT) of periconceptional multivitamin supplementation containing folic acid (0.8 mg) showed a significant 
reduction in the first occurrence of cardiovascular abnormalities (OR = 0.60; 95% CI = 0.38–0.96), especially 
ventricular septal defects (OR = 0.26; 95% CI = 0.09–0.72)21. However, two case-control studies did not find a 
reduced risk of cardiovascular system defects as a result of folic acid supplementation22,23. In our study, after bal-
ancing all measured baseline covariates by PS matching, optimal folic acid supplementation may have reduced 
the risk of cardiovascular system defects by as much as 35% compared with the nonoptimal folic acid supplemen-
tation group. This finding implies the possibility of preventing cardiovascular system defects with folic acid sup-
plementation in maternal and child health care practice during the periconceptional period. The association was 
analyzed further between the optimal folic acid supplementation and subtype of cardiovascular system defects. 
Because of lower prevalence, the association between the optimal folic acid supplementation and subtype of 
cardiovascular system defects and other birth defects were not significant statistically, but those results still were 
important clues for future study.
Two meta-analyses indicated that multivitamin supplementation with folic acid protected against oral 
clefts24,25. However, there is no strong evidence of an association between oral clefts and folic acid intake alone25. 
Some studies investigated the association between folic acid supplementation and the risk of eye, ear, face and 
neck defects, urinary system defects, musculoskeletal system defects and chromosomal abnormalities, but the 
results were inconsistent. Using the American National Birth Defects Prevention Network, Canfield investigated 
the change in the prevalence of urinary system defects after folic acid fortification and confirmed a reduction in 
the birth prevalence of renal agenesis, upper limb reduction defects, and omphalocele but an increase in obstruc-
tive genitourinary defects and Down syndrome17. Some studies have reported that multivitamin supplementation 
was associated with a reduced risk of limb reduction defects, while the associations were inconsistent for different 
limb reduction defect types17,26. A case-control study showed that a significant protective effect against Down’s 
syndrome was observed with large doses of folic acid (approximately 6 mg/d) during the first gestational month 
(OR = 0.4, 95% CI: 0.2 to 0.7)27. Unfortunately, these results were inconsistent among studies.
In our study, the prevalence of oral cleft, eye, ear, face and neck defects, respiratory system defects, digestive 
system defects and some specific birth defects (congenital hydrocephalus, ventricular septal defect, atrial septal 
defect and patent ductus arteriosus) in the optimal folic acid supplementation group was lower than in the non-
optimal folic acid supplementation group. However, there was no significant difference between the two groups. 
The lower prevalence of those specific defects could account for this lack of significance to some extent, and future 
studies with larger samples are required to further investigate these associations.
Previous observational studies usually used traditional regression methods to analyze the association between 
folic acid supplementation and birth defects20–23. However, selection bias and an imbalance of important variables 
between the groups were major problems in those observational studies28. Adjustment by specific covariates in 
regression model is adopted commonly but number of covariate, collinearity and sample size could influence the 
efficiency. The PS is a function of multiple covariates and represents the combined action of multiple covariates29. 
For an observational study, PS matching was effective in balancing confounding factors in a similar randomized 
treatment and reduced the selection bias8–10. When there were many covariates entering the model and relatively 
few events, such as the 17 covariates and 562 cases of birth defects (192.44 cases per 10,000 participants) in our 
study, PS matching was appropriate for providing an accurate estimated value compared with conventional mul-
tivariable methods30. Thus, the major strength of this study was the use of PS matching, which balanced optimal 
folic acid supplementation and nonoptimal folic acid groups on a large number of covariates by using a linear 
combination of covariates for a single score. To some extent, PS matching also reduced the confounding that may 
be present in our study. After matching, we further verified the consistency of the association between folic acid 
supplementation and birth defects by means of 3 models (including model 1, with no adjustment; model 2, with 
adjusted PS; and model 3, with adjusted covariates and PS). Our sample came from 10 urban districts and 20 rural 
counties in the province that were randomly selected according to the imbalanced population distribution and 
fertility level between rural and urban areas, and a stratified multistage sampling method was employed. Thus, 
our samples had relatively good representativeness and were suitable for evaluating the association between folic 
acid supplementation and birth defects in the population.
This study had some limitations. First, the recall bias existed possibly in this study because both the folic acid 
supplementation and risk factor information was obtained through the participant’s recall. Additionally, although 
we used the PS matching technique to balance selection bias between the two groups, the finding of our study 
might be potentially confounded by the biases related to unmeasured or hidden covariates because the covari-
ates used for PS matching were limited, resulting in incomplete or inexact matching. In our study, it is unlikely 
that a hidden variable could be completely unrelated to any of the 17 covariates used in our PS analysis. Second, 
although the policy of folic acid supplementation has promoted universal periconception folate supplementation 
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in China, the nonoptimal folic acid supplement group still may have been heterogeneous in that it included the 
women who used no or insufficient folic acid. Even though we tried our best to reduce the misclassification of 
birth defect diagnoses in our study by including a team of experts in the diagnosis of birth defects, a risk of mis-
classification of birth defect diagnoses still existed in the cases of deaths with birth defects. Finally, although our 
study included more than 29,000 women, there was limited power to detect associations due to the small number 
of women with pregnancies affected by birth defects in the study.
Conclusions
In conclusion, we observed that optimal folic acid supplementation was associated with a decreased prevalence 
of birth defects, especially of the cardiovascular system and nervous system, in Shaanxi province, Northwestern 
China. These findings may have important public health implications for the prevention of birth defects in 
Northwest China. Further prospective cohort and RCT studies are needed to confirm the preventive effects of 
folic acid supplementation.
Methods
study design and participants. Data were collected from a large population-based survey conducted 
between August and November 2013 in Shaanxi province, Northwest China. The participants were women who 
were pregnant between August 2011 and August 2013 and gave birth at a gestational age of ≥28 weeks. A sample 
size of 30,000 was estimated assuming a prevalence of birth defects of 1.4%, a relative error of 15%, a design effect 
of 2.0, two-tailed α = 0.05, and an expected response rate of 80%. Considering the imbalanced population distri-
bution and fertility level between rural and urban areas in the province, 10 urban districts and 20 rural counties 
were randomly selected, and a stratified multistage sampling method was employed to obtain the sample. First, 
six townships were randomly sampled from the chosen counties, and three streets were randomly sampled from 
the chosen districts. Second, six villages were randomly sampled from a chosen township, and six communities 
were randomly sampled from the chosen streets. Third, 30 participants were randomly sampled from the cho-
sen villages, and 60 participants were randomly sampled from the chosen communities. Approximately 32,400 
participants were expected to be sampled in the study. A total of 30,027 women were eventually enrolled in the 
survey (response rate: 92.68%). We excluded 823 women with unclear pregnancy outcomes or missing covariates, 
leaving a total of 29,204 women in this study. Written informed consent was obtained from each participant at 
the start of the survey.
Data collection. In the survey, all questionnaires, including the birth defects questionnaire and family 
questionnaire, and the field survey program were designed by Xi’an Jiaotong University Health Science Center. 
Face-to-face field surveys and data collection were carried out by uniformly trained field staff from Xi’an Jiaotong 
University Health Science Center. All the information was collected at the local village clinics and community 
health service centers. Our work was supported by local hospitals and health administration departments and the 
Ministry of Health in Shaanxi province.
A team of experts on the diagnosis of birth defects was established for this project. This team was composed 
of several senior medical technicians from the obstetrics and gynecology, ultrasound and pathology departments 
of the First Affiliated Hospital of Xi’an Jiaotong University. All cases of birth defects were diagnosed by the expert 
team using the ICD-10 to consistently and accurately code the diagnoses. For children with external anomalies, 
we collected their medical records and photographed the malformations for the final diagnosis. For children with 
congenital internal malformations, such as cardiovascular anomalies, we collected their medical records and 
conducted a free ultrasound examination at the First Affiliated Hospital of Xi’an Jiaotong University for the final 
diagnosis.
The family questionnaire was designed to collect information on maternal sociodemographic characteristics 
(including age, ethnicity, education, marital status, address of residence, occupation) and maternal exposure to 
periconceptional risk (including lifestyle, illnesses, periconceptional stress, exposure to harmful factors in the 
periconceptional environment, family history of diseases and periconceptional folic acid supplementation).
Classification of birth defects. Birth defects were classified according to the International Classification 
of Diseases Clinical Modification Codes, tenth edition, (ICD-10) as congenital malformations, deformations, and 
chromosomal abnormalities (Codes Q00–Q99), which include nervous system defects (Q00–Q07); eye, ear, face 
and neck defects (Q10–Q18); cardiovascular system defects (Q20–Q28); respiratory system defects (Q30–Q34); 
oral clefts (Q35–Q37); digestive system defects (Q38–Q45); defects of the genital organs (Q50–Q56); urinary sys-
tem defects (Q60–Q64); musculoskeletal system defects (Q65–Q79); other defects (Q80–Q89); and chromosomal 
abnormalities (Q90–Q99).
Definitions of main variables. The information on folic acid supplementation and covariates was collected 
from the participants through face-to-face interviews conducted by well-trained interviewers via standard fam-
ily questionnaires. The folic acid supplementation information included dosage per day, timing of use, and the 
period of regular use before and during pregnancy. This information was further confirmed by family members.
Optimal folic acid supplementation was defined regularly taking folic acid only or multiple micronutrients 
(≥400 µg folic acid per day) from 3 months before pregnancy through the first trimester of pregnancy for a dura-
tion of more than 3 consecutive months. Nonoptimal folic acid supplementation was defined as nonfolic acid 
supplementation, folic acid supplementation during the second and third trimesters of pregnancy, or folic acid 
supplementation for less than 3 months between the 3 months before through the 3 months after conception.
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Other important covariates were defined. Infectious disease was defined as febrile episodes (>38 °C), influ-
enza/common cold (influenza-like symptoms, seasonal influenza), infections of the kidney, bladder, urinary tract 
and genital tract and other infections affecting multiple organ systems (e.g., HIV infection, chicken pox) during 
pregnancy. Tobacco exposure was defined as active smoking (≥one cigarette per week for 3 consecutive months 
during pregnancy) or passive smoking (≥15 minutes of smoke inhalation per day for 1 consecutive month during 
pregnancy). Environmental risk factor exposure was defined as living within one kilometer of a coal mine, paper 
factory, cement factory, or power plant during pregnancy.
Quality control. All of the interviewers were trained with the same guidelines before the study. A quality 
control system was constructed during the study, and the interviewers checked themselves and were checked by 
other interviewers and by a supervisor. When errors and missing values were detected, participants were reinter-
viewed immediately.
statistical analysis. We categorized 29,204 participants into optimal folic acid supplementation and non-
optimal folic acid supplementation groups. Of the 29,204 participants, 10,593 (36.27% of 29,204) had optimal 
folic acid supplementation. The PS was a function of multiple covariables and represents the combined action of 
multiple covariates29. Given the imbalance of baseline characteristics between the two groups, PS matching was 
used; PS matching can balance potential confounders between two groups with a similar randomized treatment 
and can reduce selection bias8–10. Then, we estimated the PS for each participant using a multivariable logistic 
regression model29, in which the level of folic acid supplementation was modeled using all the baseline participant 
characteristics shown in Table 2. We used the nearest neighbor within the caliper to match each participant with 
optimal folic acid supplementation with a participant with nonoptimal folic acid supplementation; thus, 9,293 
(87.73% of the 10,593) participants with optimal folic acid supplementation were matched to 9,293 participants 
with nonoptimal folic acid supplementation and a similar estimated PS31. In our matching algorithm, we matched 
each participant with optimal folic acid supplementation with a participant with nonoptimal folic acid supple-
mentation who had a similar PS to five decimal places. The nearest neighbor within caliper matching function 
was as follows:
= || − || ∈P P P j IC( ) min ,i
j
i j 0
ε|| − || < ∈P P j I,i j 0
Pi: propensity score of the optimal folic acid supplementation group; Pj: propensity score of the nonoptimal folic 
acid supplementation group; I0: the set of the nonoptimal folic acid supplementation group; C(Pi): the matching 
nonoptimal folic acid supplementation participant for the optimal folic acid supplementation participant; ε: tol-
erance for matching (caliper). The absolute standardized difference based on the chi-square and Student’s t-tests 
was used to compare the baseline characteristics of the participants with optimal folic acid supplementation and 
those with nonoptimal folic acid supplementation before and after matching10,32. The prematch mean PS for the 
participants with optimal folic acid supplementation and nonoptimal folic acid supplementation were 0.39809 
and 0.34259, respectively (absolute standardized difference = 70.58%, P < 0.001). After matching, the mean PS for 
the higher of the participants with optimal folic acid supplementation and nonoptimal folic acid supplementation 
were 0.38425 and 0.38425, respectively (absolute standardized difference = 0.01%, P = 0.999).
Then, we used univariate conditional logistic regression models to estimate the association of optimal folic 
acid supplementation with various birth defects and overall birth defects. We conducted sensitivity analyses using 
two approaches to assess the robustness of our findings regarding the effect of folic acid supplementation on birth 
outcomes to changes in the analytic approach. To address concerns about incomplete matching, we analyzed data 
from all 29,204 participants using GEE adjustment for PS and all baseline covariates and subclassification based 
on tertiles of PS.
The data were managed by a database using EpiData Version 3.02 (The EpiData Association, Odense, 
Denmark), and data entries were duplicated. All of the analyses were performed with STATA version 12.0 soft-
ware (STATA Corporation, College Station, TX, USA). The level of significance was set at P < 0.05.
ethics statement. The Human Research Ethics Committee of the Xi’an Jiaotong University Health Science 
Center approved this study (No. 2012008). Written informed consent was obtained from all adult participants 
after a detailed explanation of the research. All research was performed in accordance with relevant guidelines 
and regulations.
Data Availability
All data generated or analyzed during this study are included in this published article.
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